Improving the tolerability of osimertinib by identifying its toxic limit

BACKGROUND: Osimertinib is the cornerstone in the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer (NSCLC). Nonetheless, ±25% of patients experience severe treatment-related toxicities. Currently, it is impossible to identify patients at risk of severe toxicity before...

Descripción completa

Detalles Bibliográficos
Autores principales: Agema, Bram C., Veerman, G. D. Marijn, Steendam, Christi M. J., Lanser, Daan A. C., Preijers, Tim, van der Leest, Cor, Koch, Birgit C. P., Dingemans, Anne-Marie C., Mathijssen, Ron H. J., Koolen, Stijn L. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168866/
https://www.ncbi.nlm.nih.gov/pubmed/35677320
http://dx.doi.org/10.1177/17588359221103212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168866/
https://www.ncbi.nlm.nih.gov/pubmed/35677320
http://dx.doi.org/10.1177/17588359221103212

Ejemplares similares